Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma

Andrew M. Wilson, Linda C. Orr, Erika J. Sims, Owen J. Dempsey, Brian J. Lipworth

    Research output: Contribution to journalArticle

    89 Citations (Scopus)

    Abstract

    To compare the antiasthmatic efficacy of inflammatory mediator blockade versus topical corticosteroid therapy in patients with seasonal allergic rhinitis (SAR) and asthma, 14 patients were enrolled into a single-blind, double-dummy, placebo-controlled crossover study comparing 2 wk therapy of (1) 400 microgram orally inhaled budesonide plus 200 microgram intranasal budesonide (BUD) or (2) 10 mg oral montelukast plus 10 mg oral cetirizine (ML + CZ). Before each treatment period, patients received 7 to 10 d placebo washout. All treatments were given once daily in the morning. Throughout the study, patients recorded the following domiciliary measures: peak expiratory flow (PEF), rescue inhaler requirement, asthma symptoms, and daily activity score. Laboratory measurements were made at trough of adenosine monophosphate (AMP) bronchial challenge and exhaled nitric oxide (NO). Compared with pooled placebo (PL), there were significant (p <0.05) improvements in all domiciliary measures with both treatments (mean PEF [L/min] PL: 463; BUD: 478; ML + CZ: 483). For geometric mean AMP PC(20) (mg/ml), there was an improvement (p <0.05), compared with PL (47), for ML + CZ (133) but not for BUD (51); whereas for NO (ppb) there was significant suppression with BUD (7.6) but not ML + CZ (11.5) compared with PL (13.6). In conclusion, both combined mediator blockade and combined topical corticosteroids are equally effective antiasthma therapy in patients with asthma and SAR.
    Original languageEnglish
    Pages (from-to)1297-301
    Number of pages5
    JournalAmerican Journal of Respiratory and Critical Care Medicine
    Volume162
    Issue number4
    Publication statusPublished - 1 Oct 2000

    Fingerprint

    Anti-Asthmatic Agents
    Budesonide
    Adrenal Cortex Hormones
    Asthma
    Placebos
    Seasonal Allergic Rhinitis
    montelukast
    Adenosine Monophosphate
    Nitric Oxide
    Therapeutics
    Cetirizine
    Nebulizers and Vaporizers
    Cross-Over Studies
    Allergic Rhinitis

    Cite this

    @article{c2f51aef25f44674ada285cd7dbfabd2,
    title = "Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma",
    abstract = "To compare the antiasthmatic efficacy of inflammatory mediator blockade versus topical corticosteroid therapy in patients with seasonal allergic rhinitis (SAR) and asthma, 14 patients were enrolled into a single-blind, double-dummy, placebo-controlled crossover study comparing 2 wk therapy of (1) 400 microgram orally inhaled budesonide plus 200 microgram intranasal budesonide (BUD) or (2) 10 mg oral montelukast plus 10 mg oral cetirizine (ML + CZ). Before each treatment period, patients received 7 to 10 d placebo washout. All treatments were given once daily in the morning. Throughout the study, patients recorded the following domiciliary measures: peak expiratory flow (PEF), rescue inhaler requirement, asthma symptoms, and daily activity score. Laboratory measurements were made at trough of adenosine monophosphate (AMP) bronchial challenge and exhaled nitric oxide (NO). Compared with pooled placebo (PL), there were significant (p <0.05) improvements in all domiciliary measures with both treatments (mean PEF [L/min] PL: 463; BUD: 478; ML + CZ: 483). For geometric mean AMP PC(20) (mg/ml), there was an improvement (p <0.05), compared with PL (47), for ML + CZ (133) but not for BUD (51); whereas for NO (ppb) there was significant suppression with BUD (7.6) but not ML + CZ (11.5) compared with PL (13.6). In conclusion, both combined mediator blockade and combined topical corticosteroids are equally effective antiasthma therapy in patients with asthma and SAR.",
    author = "Wilson, {Andrew M.} and Orr, {Linda C.} and Sims, {Erika J.} and Dempsey, {Owen J.} and Lipworth, {Brian J.}",
    year = "2000",
    month = "10",
    day = "1",
    language = "English",
    volume = "162",
    pages = "1297--301",
    journal = "American Journal of Respiratory and Critical Care Medicine",
    issn = "1073-449X",
    publisher = "American Thoracic Society",
    number = "4",

    }

    Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. / Wilson, Andrew M.; Orr, Linda C.; Sims, Erika J.; Dempsey, Owen J.; Lipworth, Brian J.

    In: American Journal of Respiratory and Critical Care Medicine, Vol. 162, No. 4 , 01.10.2000, p. 1297-301.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma

    AU - Wilson, Andrew M.

    AU - Orr, Linda C.

    AU - Sims, Erika J.

    AU - Dempsey, Owen J.

    AU - Lipworth, Brian J.

    PY - 2000/10/1

    Y1 - 2000/10/1

    N2 - To compare the antiasthmatic efficacy of inflammatory mediator blockade versus topical corticosteroid therapy in patients with seasonal allergic rhinitis (SAR) and asthma, 14 patients were enrolled into a single-blind, double-dummy, placebo-controlled crossover study comparing 2 wk therapy of (1) 400 microgram orally inhaled budesonide plus 200 microgram intranasal budesonide (BUD) or (2) 10 mg oral montelukast plus 10 mg oral cetirizine (ML + CZ). Before each treatment period, patients received 7 to 10 d placebo washout. All treatments were given once daily in the morning. Throughout the study, patients recorded the following domiciliary measures: peak expiratory flow (PEF), rescue inhaler requirement, asthma symptoms, and daily activity score. Laboratory measurements were made at trough of adenosine monophosphate (AMP) bronchial challenge and exhaled nitric oxide (NO). Compared with pooled placebo (PL), there were significant (p <0.05) improvements in all domiciliary measures with both treatments (mean PEF [L/min] PL: 463; BUD: 478; ML + CZ: 483). For geometric mean AMP PC(20) (mg/ml), there was an improvement (p <0.05), compared with PL (47), for ML + CZ (133) but not for BUD (51); whereas for NO (ppb) there was significant suppression with BUD (7.6) but not ML + CZ (11.5) compared with PL (13.6). In conclusion, both combined mediator blockade and combined topical corticosteroids are equally effective antiasthma therapy in patients with asthma and SAR.

    AB - To compare the antiasthmatic efficacy of inflammatory mediator blockade versus topical corticosteroid therapy in patients with seasonal allergic rhinitis (SAR) and asthma, 14 patients were enrolled into a single-blind, double-dummy, placebo-controlled crossover study comparing 2 wk therapy of (1) 400 microgram orally inhaled budesonide plus 200 microgram intranasal budesonide (BUD) or (2) 10 mg oral montelukast plus 10 mg oral cetirizine (ML + CZ). Before each treatment period, patients received 7 to 10 d placebo washout. All treatments were given once daily in the morning. Throughout the study, patients recorded the following domiciliary measures: peak expiratory flow (PEF), rescue inhaler requirement, asthma symptoms, and daily activity score. Laboratory measurements were made at trough of adenosine monophosphate (AMP) bronchial challenge and exhaled nitric oxide (NO). Compared with pooled placebo (PL), there were significant (p <0.05) improvements in all domiciliary measures with both treatments (mean PEF [L/min] PL: 463; BUD: 478; ML + CZ: 483). For geometric mean AMP PC(20) (mg/ml), there was an improvement (p <0.05), compared with PL (47), for ML + CZ (133) but not for BUD (51); whereas for NO (ppb) there was significant suppression with BUD (7.6) but not ML + CZ (11.5) compared with PL (13.6). In conclusion, both combined mediator blockade and combined topical corticosteroids are equally effective antiasthma therapy in patients with asthma and SAR.

    M3 - Article

    VL - 162

    SP - 1297

    EP - 1301

    JO - American Journal of Respiratory and Critical Care Medicine

    JF - American Journal of Respiratory and Critical Care Medicine

    SN - 1073-449X

    IS - 4

    ER -